Report LibraryAll Reports
Datamonitor Healthcare Infectious Diseases Disease Analysis: Meningococcal Vaccines
January 10, 2022
The US meningococcal vaccines market is expected to grow over the forecast period due to incremental increases in MenACWY and MenB coverage rates in adolescents and young adults before the anticipated introduction of GlaxoSmithKline’s and Pfizer’s pentavalent vaccines in H1 2024. Beyond this period, market growth will be driven by the uptake of pentavalent vaccines, which could significantly boost coverage for the MenB component by linking the higher coverage rates observed with the booster dose of MenACWY in adolescents (54.4% in 2020) to the suboptimal coverage rates with MenB vaccines (28.4% of 17-year-olds received at least one MenB dose in 2020). However, this will depend on the strength of Advisory Committee on Immunization Practices (ACIP) recommendations. The pentavalent vaccines would also be more convenient for physicians and patients as they would reduce the total number of doses required during adolescence from four (two MenACWY + two MenB) to three.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Meningococcal Vaccines and Other Meningococcus-Specific Agents (Antibacterial)|